Cargando…
Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia
The importance of medication adherence in sustaining control of schizophrenic symptoms has generated a great deal of interest in comparing levels of treatment adherence with different antipsychotic agents. However, the bulk of the research has yielded results that are often inconsistent. In this pro...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2762365/ https://www.ncbi.nlm.nih.gov/pubmed/19851516 |
_version_ | 1782172915554320384 |
---|---|
author | Ren, Xinhua S Herz, Lawrence Qian, Shirley Smith, Eric Kazis, Lewis E |
author_facet | Ren, Xinhua S Herz, Lawrence Qian, Shirley Smith, Eric Kazis, Lewis E |
author_sort | Ren, Xinhua S |
collection | PubMed |
description | The importance of medication adherence in sustaining control of schizophrenic symptoms has generated a great deal of interest in comparing levels of treatment adherence with different antipsychotic agents. However, the bulk of the research has yielded results that are often inconsistent. In this prospective, observational study, we assessed the measurement properties of 3 commonly used, pharmacy-based measures of treatment adherence with antipsychotic agents in schizophrenia using data from the Veterans Health Administration during 2000 to 2005. Patients were selected if they were on antipsychotics and diagnosed with schizophrenia (N = 18,425). A gap of ≥30 days (with no filled index medication) was used to define discontinuation of treatment as well as medication “episodes,” or the number of times a patient returned to the same index agent after discontinuation of treatment within a 1-year period. The study found that the 3 existing measures differed in their approaches in measuring treatment adherence, suggesting that studies using these different measures would generate different levels of treatment adherence across antipsychotic agents. Considering the measurement problems associated with each existing approach, we offered a new, medication episode-specific approach, which would provide a fairer comparison of the levels of treatment adherence across different antipsychotic agents. |
format | Text |
id | pubmed-2762365 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-27623652009-10-22 Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia Ren, Xinhua S Herz, Lawrence Qian, Shirley Smith, Eric Kazis, Lewis E Neuropsychiatr Dis Treat Original Research The importance of medication adherence in sustaining control of schizophrenic symptoms has generated a great deal of interest in comparing levels of treatment adherence with different antipsychotic agents. However, the bulk of the research has yielded results that are often inconsistent. In this prospective, observational study, we assessed the measurement properties of 3 commonly used, pharmacy-based measures of treatment adherence with antipsychotic agents in schizophrenia using data from the Veterans Health Administration during 2000 to 2005. Patients were selected if they were on antipsychotics and diagnosed with schizophrenia (N = 18,425). A gap of ≥30 days (with no filled index medication) was used to define discontinuation of treatment as well as medication “episodes,” or the number of times a patient returned to the same index agent after discontinuation of treatment within a 1-year period. The study found that the 3 existing measures differed in their approaches in measuring treatment adherence, suggesting that studies using these different measures would generate different levels of treatment adherence across antipsychotic agents. Considering the measurement problems associated with each existing approach, we offered a new, medication episode-specific approach, which would provide a fairer comparison of the levels of treatment adherence across different antipsychotic agents. Dove Medical Press 2009 2009-10-12 /pmc/articles/PMC2762365/ /pubmed/19851516 Text en © 2009 Ren et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Original Research Ren, Xinhua S Herz, Lawrence Qian, Shirley Smith, Eric Kazis, Lewis E Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia |
title | Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia |
title_full | Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia |
title_fullStr | Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia |
title_full_unstemmed | Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia |
title_short | Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia |
title_sort | measurement of treatment adherence with antipsychotic agents in patients with schizophrenia |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2762365/ https://www.ncbi.nlm.nih.gov/pubmed/19851516 |
work_keys_str_mv | AT renxinhuas measurementoftreatmentadherencewithantipsychoticagentsinpatientswithschizophrenia AT herzlawrence measurementoftreatmentadherencewithantipsychoticagentsinpatientswithschizophrenia AT qianshirley measurementoftreatmentadherencewithantipsychoticagentsinpatientswithschizophrenia AT smitheric measurementoftreatmentadherencewithantipsychoticagentsinpatientswithschizophrenia AT kazislewise measurementoftreatmentadherencewithantipsychoticagentsinpatientswithschizophrenia |